Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs

Patent metadata

Field	Value
Publication number	US-11077080-B2
Application number	US-201514736004-A
Country	US
Kind code	B2
Filing date	Jun 10, 2015
Priority date	Sep 10, 2008
Publication date	Aug 3, 2021
Grant date	Aug 3, 2021

Abstract

The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-β-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.

First claim

The invention claimed is:

1. Method for treating patients suffering from one or more of depression; bipolar disorder; schizophrenia; anxiety; stress; panic; phobias; obsessive compulsive disorders; behavioral disorders; pain; fibromyalgia; eating disorders selected from the group consisting of bulimia and anorexia; migraine; and neurodegenerative disorders selected from the group consisting of Alzheimer's disease, Huntington's disease and Parkinson's disease, comprising the administration to said patients of:
a) at least one psychotropic drug; and
b) at least one connexin-blocking agent;
the drug a) and the agent b) are administrated simultaneously, separately or spread out over time;
wherein the at least one psychotropic drug is a serotoninergic effector selected from the group consisting of chlorpromazine, trimipramine, clozapine, olanzapine, cyamemazine, flupentixol, nefopam, fluvoxamine, clomipramine, sertraline, fluoxetine, citalopram, escitalopram, paroxetine, amitriptyline, duloxetine, venlafaxine, buspirone, carpipramine, zolmitriptan, sumatriptan, naratriptan, indoramine, ergotamine, ergotamine tartrate, pizotifene, pipamperone, methysergide, pizotyline, tianeptine, milnacipran, amitriptylene, trimipramine, viloxazine, tianeptine, hypericum, lithium, and combinations thereof,
wherein the at least one connexin-blocking agent is selected from the group consisting of meclofenamic acid, 18-β-glycyrrhetinic acid, mefloquine, 2-APB and combinations thereof,
wherein the at least one connexin-blocking agent is administered at a dose at least 10 to 25-fold less than a dose having an anti-inflammatory effect.

2. The method according to claim 1 , wherein the serotoninergic effector is amitriptyline.

3. The method according to claim 1 , wherein the serotoninergic effector is amitriptyline and the connexin-blocking agent is mefloquine.

Assignees

• Commissariat Energie Atomique
• Bio Modeling Systems Ou Bmsystems
• Commissariat A Lenergie Atomique Aux Energies Alternatives

Inventors

• Mouthon Franck
• Charveriat Mathieu
• Deslys Jean-Philippe
• Iris François

Classifications

• A61K31/137

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

• A61K31/4525

  containing a five-membered ring with oxygen as a ring hetero atom · CPC title

• A61K31/195

  having an amino group · CPC title

• A61K31/343

  condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone · CPC title

• A61K31/165

  having aromatic rings, e.g. colchicine, atenolol, progabide · CPC title